MapLight Moves Toward Phase 3 Schizophrenia Trial; VISTA Study Enrollment Continues
MapLight Therapeutics (MPLT) reported a Q3 2026 net loss of $51.6M, up from $29.4M YoY. The company plans a Phase 3 trial for ML-007C-MA in schizophrenia and continues enrollment in a Phase 2 trial for Alzheimer's disease psychosis. MPLT has $463.4M in cash and expects funds to last through 2028. The stock closed at $7.25, up 2.55%.
How this was made
The 30-second read
Why it matters
The initiation of a confirmatory Phase 3 trial and a $150 million private placement provide clear forward‑looking catalysts that could move the stock ahead of the 2028 readout.
Market read
The news offers a material catalyst for MPLT and may influence peer biotech valuations.
What to watch
Potential dilution from the private placement and the company's decision to pause pre‑clinical programs could limit near‑term growth.
Background
MapLight Therapeutics is a clinical‑stage biotech developing muscarinic agonists for CNS disorders. The company reported a Q3 net loss of $51.6 million and cash of $463.4 million.
Ticker impact
MapLight Therapeutics announced start‑up of its confirmatory Phase 3 schizophrenia trial (ZEPHYR‑2) and disclosed a $150 million private placement to fund the program.
likely upward pressure as investors price in potential Phase 3 data and the fresh funding.
Biotech stocks typically rally on forward‑looking trial news and large financing, especially when cash runway extends to 2028.
Market effects
May boost sentiment for CNS‑focused biotech sector and peers developing muscarinic agonists.
Limited to U.S. biotech investors; no broader regional effect.
Modest global relevance, primarily affecting biotech and pharma investors.
Counterpoint
If Phase 3 enrollment delays or adverse data occur, the stock could face sharp downside despite the cash infusion.
Key entities
- companyMapLight Therapeutics, Inc.
Clinical‑stage biopharma developing CNS therapies.

